Benefit assessment by the Federal Joint Committee

被引：0

作者：

Schmedders, M. ^{[1
]}

Janatzek, S. ^{[2
]}

Zimmer, B. ^{[3
]}

机构：

[1] GKV Spitzenverband, D-10117 Berlin, Germany

[2] Med Dienst Spitzenverbandes Bund Krankenkasse, Essen, Germany

[3] Med Dienst Krankenversicherung Nordrhein, Kompetenz Ctr Onkol, Dusseldorf, Germany

来源：

UROLOGE | 2011年 / 50卷 / 08期

关键词：

Benefit assessment; Prostate cancer; Low dose rate brachytherapy; Federal Joint Committee; PREFERE; ESTRO/EAU/EORTC RECOMMENDATIONS; LEAD TIME; PROSTATE;

D O I：

10.1007/s00120-011-2545-3

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

One of the Federal Joint Committee's duties is to assess benefit, need, and cost-effectiveness of diagnostic and therapeutic approaches. The aim is to decide whether they can be provided within the statutory health care system in Germany. The systematic assessment concerning low dose rate brachytherapy with permanent seed implantation for treatment of men with localized prostate cancer revealed that sufficient scientific evidence for its benefit compared to therapeutic alternatives is still missing. In 2009, the Federal Joint Committee recommended a randomized controlled trial in order to evaluate the different therapies. Based on a concept developed by the National Association of Statutory Health Insurance Funds urology and radiooncology experts and other protagonists are currently working on the steps to be taken for implementation of a preference-based randomized controlled trial to compare radical prostatectomy, percutaneous radiotherapy, low dose rate brachytherapy with permanent seed implantation, and active surveillance in the treatment of low or early intermediate risk prostate cancer.

引用

页码：938 / 943

页数：6

共 50 条

[1] Decision of the Federal Joint Committee on Screening for Chorionicity - Benefit Assessment in the Absence of Screening Studies
Schwalm, A.
Bertelsmann, H.
Gruber, S.
Wietschel, G.
Matthias, K.
[J]. GESUNDHEITSWESEN, 2013, 75 (01) : 13 - 21
[2] Joint Federal Committee issues first Orders for the Cost-benefit Assessment of Pharmaceuticals
Reis-Steinert, Kristine
[J]. ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2010, 104 (01): : 9 - 9
[3] Early Benefit Assessment of Pharmaceuticals in Germany: Manufacturers' Expectations versus the Federal Joint Committee's Decisions
Fischer, Katharina E.
Stargardt, Tom
[J]. MEDICAL DECISION MAKING, 2014, 34 (08) : 1030 - 1047
[4] Federal Joint Committee
Henkel, R. A. Markus
[J]. RADIOLOGE, 2014, 54 (10): : 1042 - 1042
[5] Joint Federal Committee
Lundershausen, Ellen
[J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2010, 107 (11): : 196 - 196
[6] GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT - WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?
Scheler, E.
Stratil, A.
Roxlau, T.
Bonduelle, D.
[J]. VALUE IN HEALTH, 2018, 21 : S197 - S197
[7] Assessment of the Generalisability of Clinical Trial Results in the Federal Joint Committee
Perleth, Matthias
[J]. ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2009, 103 (06): : 412 - 414
[8] INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY
Dintsios, Charalabos-Markos
Schlenkrich, Sara
[J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (02) : 196 - 204
[9] APPROPRIATE COMPARATIVE TREATMENTS FOR EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY. COMPARING THE SUGGESTIONS BY THE JOINT FEDERAL COMMITTEE (GBA) AND THE PHARMACEUTICAL COMPANIES
Ruof, J.
Scherer, J.
Schulenburg, J. M.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A490 - A490
[10] AN EARLY ASSESSMENT OF THE GERMAN FEDERAL JOINT COMMISSION RESOLUTIONS OF ADDITIONAL CLINICAL BENEFIT
McBride, D.
Kilburg, A.
Mauskopf, J.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A311 - A311

← 1 2 3 4 5 →